Louisiana State Employees Retirement System Acquires New Holdings in STAAR Surgical (NASDAQ:STAA)

Louisiana State Employees Retirement System acquired a new position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 24,400 shares of the medical instruments supplier's stock, valued at approximately $762,000.

A number of other institutional investors also recently bought and sold shares of the company. Clear Street Markets LLC purchased a new stake in STAAR Surgical in the 3rd quarter valued at about $29,000. Nisa Investment Advisors LLC lifted its holdings in shares of STAAR Surgical by 415.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,445 shares of the medical instruments supplier's stock worth $98,000 after acquiring an additional 1,971 shares during the last quarter. Covestor Ltd boosted its position in shares of STAAR Surgical by 82,466.7% during the 3rd quarter. Covestor Ltd now owns 2,477 shares of the medical instruments supplier's stock worth $100,000 after purchasing an additional 2,474 shares during the period. Van ECK Associates Corp increased its holdings in STAAR Surgical by 44.5% in the 3rd quarter. Van ECK Associates Corp now owns 3,184 shares of the medical instruments supplier's stock valued at $128,000 after purchasing an additional 980 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in STAAR Surgical by 171.5% in the third quarter. PNC Financial Services Group Inc. now owns 3,755 shares of the medical instruments supplier's stock valued at $151,000 after purchasing an additional 2,372 shares during the period. 96.70% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, Director Aimee S. Weisner bought 1,750 shares of the business's stock in a transaction dated Thursday, March 14th. The shares were acquired at an average cost of $38.11 per share, with a total value of $66,692.50. Following the acquisition, the director now directly owns 10,864 shares of the company's stock, valued at approximately $414,027.04. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.10% of the stock is owned by company insiders.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock traded up $0.07 during trading hours on Friday, hitting $46.96. The company had a trading volume of 335,626 shares, compared to its average volume of 759,304. The company's 50-day moving average is $39.86 and its two-hundred day moving average is $35.64. The company has a market cap of $2.31 billion, a P/E ratio of 109.21 and a beta of 0.86. STAAR Surgical has a twelve month low of $26.66 and a twelve month high of $73.13.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The company had revenue of $76.27 million during the quarter, compared to analysts' expectations of $75.94 million. During the same period last year, the firm earned $0.04 earnings per share. STAAR Surgical's revenue was up 19.1% on a year-over-year basis. Sell-side analysts expect that STAAR Surgical will post 0.03 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on STAA. Stifel Nicolaus reaffirmed a "buy" rating and issued a $50.00 price objective on shares of STAAR Surgical in a research note on Monday, April 1st. Canaccord Genuity Group upped their target price on shares of STAAR Surgical from $32.00 to $46.00 and gave the stock a "hold" rating in a research note on Monday, April 8th. Mizuho increased their target price on shares of STAAR Surgical from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, April 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a research report on Thursday, April 4th. Finally, William Blair raised STAAR Surgical from a "market perform" rating to an "outperform" rating in a research note on Thursday, April 4th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical has a consensus rating of "Hold" and an average target price of $46.38.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.